MANGALAM

Mangalam Drugs and Organics Share Price

₹104.43 -1.94 (-1.82%)

21 Nov, 2024 14:29

SIP TrendupStart SIP in MANGALAM

Start SIP

Performance

  • Low
  • ₹104
  • High
  • ₹106
  • 52 Week Low
  • ₹91
  • 52 Week High
  • ₹145
  • Open Price₹105
  • Previous Close₹106
  • Volume13,471

Investment Returns

  • Over 1 Month -11.57%
  • Over 3 Month -14.18%
  • Over 6 Month + 2.78%
  • Over 1 Year + 8.29%
SIP Lightning

Smart Investing Starts Here Start SIP with Mangalam Drugs and Organics for Steady Growth!

Invest Now

Mangalam Drugs and Organics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 17.6
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 165
  • P/B Ratio
  • 1.2
  • Average True Range
  • 4.08
  • EPS
  • 5.94
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.38
  • RSI
  • 35.63
  • MFI
  • 53.73

Mangalam Drugs and Organics Financials

Mangalam Drugs and Organics Technicals

EMA & SMA

Current Price
₹104.43
-1.94 (-1.82%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹110.23
  • 50 Day
  • ₹114.98
  • 100 Day
  • ₹115.41
  • 200 Day
  • ₹113.18

Resistance and Support

106.89 Pivot Speed
  • R3 109.92
  • R2 109.08
  • R1 107.73
  • S1 105.54
  • S2 104.70
  • S3 103.35

What's your outlook on Mangalam Drugs and Organics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mangalam Drugs & Orgs. has an operating revenue of Rs. 356.05 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of -3% needs improvement, ROE of -6% is poor and needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mangalam Drugs and Organics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-13 Quarterly Results
2024-05-21 Audited Results
2024-03-15 Others Inter alia to consider and approve: The proposal of Scheme of Merger.
2024-02-13 Quarterly Results

Mangalam Drugs and Organics F&O

Mangalam Drugs and Organics Shareholding Pattern

50.3%
0.11%
0%
44.91%
4.68%

About Mangalam Drugs and Organics

  • NSE Symbol
  • MANGALAM
  • BSE Symbol
  • 532637
  • Chairman & Managing Director
  • Mr. Govardhan Murlidhar Dhoot
  • ISIN
  • INE584F01014

Similar Stocks to Mangalam Drugs and Organics

Mangalam Drugs and Organics FAQs

Mangalam Drugs and Organics share price is ₹104 As on 21 November, 2024 | 14:15

The Market Cap of Mangalam Drugs and Organics is ₹165.3 Cr As on 21 November, 2024 | 14:15

The P/E ratio of Mangalam Drugs and Organics is 17.6 As on 21 November, 2024 | 14:15

The PB ratio of Mangalam Drugs and Organics is 1.2 As on 21 November, 2024 | 14:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23